National Alzheimer's Coordinating Center

项目总结 新冠肺炎大流行对世界各地脆弱的老龄化人口产生了重大影响。 阿尔茨海默病相关性痴呆患者的临床护理特别容易受到Covid- 19和新冠肺炎一直与患者的不良预后有关。在这个国家阿尔茨海默氏症 协调中心(NACC)行政补充提案，我们正在为 研究有新冠肺炎病史的AD患者预后不良的遗传因素。 我们正在利用和部署新的新冠肺炎表型数据收集工具来治疗阿尔茨海默氏症 疾病研究中心联盟(ADRC)。这项工作将提供一个高影响力，创新和 使用常规临床护理数据进行定量和准确表型的经济论证 病人。医疗保险和医疗补助服务中心(CMS)管理索赔形式的护理数据 而电子健康记录(EHR)将是本次演示的基础。NACC将与 NIAGADS和三个试点网站，华盛顿大学圣路易斯分校、哥伦比亚大学和印第安纳大学 ADRC。这项工作将在三个目标下完成。首先，我们将在试点阶段支持更多的临床研究 临床网站，并将部署新的预期数据收集工具，以支持后急性后遗症 新冠肺炎。第二，我们将评估EHR和CMS数据的可行性，并开始与 ADRC试点地点和NIA。最后，我们将与NIAGADS合作，实现协作分析 整合登记参与者数据的表型和基因数据。这项提案如果获得资金，将放在一起 AD相关表型和新冠肺炎研究的重要基础设施。

PROJECT SUMMARY The Covid-19 pandemic has had a substantial impact on vulnerable aging populations across the world. Clinical care of patients with Alzheimer’s associated dementia are especially vulnerable to the effects of Covid- 19 and Covid-19 has been associated with poor outcomes in patients. In this National Alzheimer’s Coordinating Center (NACC) Administrative Supplement proposal, we are providing the infrastructure for investigating the genetic factors associated with poor outcomes in patients with AD and a history of Covid-19. We are leveraging and deploying new data collection instruments for Covid-19 phenotypes to the Alzheimer’s Disease Research Centers Consortium (ADRCs). This work will provide a high impact, innovative, and economical demonstration of the use of routine clinical care data to quantitatively and accurately phenotype patients. Care data in the form of Centers for Medicare and Medicaid Services (CMS) administrative claims and electronic health record (EHR) will be the basis for this demonstration. NACC will collaborate with NIAGADS and three pilot sites, Washington University St. Louis, Columbia University and Indiana University ADRCs. This work will be done in three aims. First, we will support additional clinical research at the pilot clinical sites and will deploy new prospective data collection instruments to support post acute sequelae of Covid-19. Second, we will assess feasibility of and begin to collect EHR and CMS data in partnership with the ADRC pilot sites and the NIA. Finally, we will collaborate with NIAGADS to enable collaborative analysis of integrated phenotype and genetic data of enrolled participant data. Together this proposal, if funded, will place important infrastructure for the study of AD associated phenotypes and Covid-19.